Boston Scientific Corporation vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Boston Scientific Corporation trades at $43.06 (market cap $66.37B), while iShares 10 20 Year Treasury Bond ETF trades at $98.52. The key difference: iShares 10 20 Year Treasury Bond ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | TLH | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Fixed Income |
52-Week High | $108.14 | $105.36 |
52-Week Low | $42.63 | $97.13 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
TLH stock trades at $97.98, down 0.53% today, with a bearish technical signal from moving averages but bullish oscillators. The company has announced dividends for H1-26 and H2-26, yet key financial ratios are unavailable. Recent news highlights broader market volatility from Fed policy uncertainty and geopolitical tensions.
The outlook is cautious due to missing fundamental data and bearish technicals. Risks include macroeconomic headwinds and lack of visibility on earnings. Investment opportunity hinges on future financial disclosures and market sentiment shifts.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →